Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

The Biology of Small Cell Lung Cancer

At a Glance

Small cell lung cancer (SCLC) is an aggressive cancer driven by the loss of two critical tumor-suppressor genes, TP53 and RB1. Researchers classify SCLC into four molecular subtypes based on genetic master switches, helping to guide future personalized therapies and immunotherapy options.

To understand small cell lung cancer (SCLC), it helps to look at the “instruction manual” inside your cells. Every cell has genes that act like brakes to stop it from growing too fast. In SCLC, these brakes have been almost entirely removed, leading to the rapid growth characteristic of the disease [1][2].

The “Brakes”: TP53 and RB1

In nearly every case of SCLC, two critical “brake” genes are broken or missing: TP53 and RB1 [3][4].

  • TP53 (The Guardian): This gene normally stops a cell from dividing if its DNA is damaged. It either fixes the damage or tells the cell to self-destruct for the safety of the body. When TP53 is mutated (broken), the cell continues to divide even with massive errors in its code [5][6].
  • RB1 (The Gatekeeper): This gene controls the timing of cell division. It ensures a cell only divides when it is supposed to. When RB1 is lost, the cell gets a permanent “green light” to multiply as fast as possible [5][7].

The loss of both TP53 and RB1 simultaneously is the “signature” of SCLC. It forces cells into a state of lineage plasticity, meaning they lose their identity and become aggressive, fast-growing “chameleons” [8][7].

The Four Molecular Subtypes

While all SCLC shares the loss of these brakes, researchers have discovered that the cancer can take four different “personalities” or molecular subtypes. These are defined by which “master switch” (a transcription factor) is turned on [9][10].

Subtype Master Switch Key Feature
SCLC-A ASCL1 The most common type; highly neuroendocrine (behaves like nerve/hormone cells) [9][11].
SCLC-N NEUROD1 Also neuroendocrine; may grow and spread slightly differently than SCLC-A [9][11].
SCLC-P POU2F3 Not neuroendocrine; often found in patients with less smoking history [9][4].
SCLC-I Inflamed Replaces older classifications. It is characterized by high immune cell infiltration and tends to respond better to immunotherapy [9][4].

Understanding these subtypes is the future of SCLC care, as researchers are looking for treatments that target the specific “master switch” of your tumor [12][13].

How SCLC Differs from NSCLC

Small cell lung cancer is biologically a different “beast” than non-small cell lung cancer (NSCLC):

  • Origin: SCLC starts in neuroendocrine cells (cells that receive signals from the nervous system and release hormones), while NSCLC starts in the lining of the lungs [4][14].
  • Drivers: NSCLC often has “on-switches” like EGFR or ALK mutations that can be turned off with pills. SCLC is driven by the loss of “off-switches” (TP53 and RB1), which is much harder to treat with traditional targeted therapy [15][14].

When One Cancer Becomes Another: Transformation

In some rare cases, a patient might start with a specific type of NSCLC (often adenocarcinoma with an EGFR mutation). Over time, usually as a way to hide from treatment, that cancer can “transform” into SCLC [16][17].

This happens through lineage plasticity—the cancer cell essentially re-writes its own identity to survive [8][18]. When this transformation occurs, the cancer begins to look and act like SCLC under the microscope and usually requires a switch to SCLC-specific chemotherapy [19][20]. Finding TP53 and RB1 mutations in an original NSCLC biopsy can sometimes warn doctors that this transformation might happen in the future [3][21].

Return to Understanding Your Small Cell Lung Cancer Diagnosis.

Common questions in this guide

What genes cause small cell lung cancer?
In nearly every case of small cell lung cancer, two critical genes called TP53 and RB1 are broken or missing. These genes normally act as brakes to stop cells from dividing uncontrollably, and their loss allows the cancer to multiply rapidly.
What are the molecular subtypes of small cell lung cancer?
Researchers have identified four molecular subtypes of small cell lung cancer: SCLC-A, SCLC-N, SCLC-P, and SCLC-I. These subtypes are defined by the specific master switches driving the cancer and may eventually help doctors tailor personalized treatments.
How is small cell lung cancer different from non-small cell lung cancer?
Small cell lung cancer starts in neuroendocrine cells and is driven by the loss of tumor-suppressing genes, making it very aggressive. Non-small cell lung cancer typically starts in the lung lining and is more frequently driven by gene mutations that can be targeted with oral medications.
Can non-small cell lung cancer turn into small cell lung cancer?
Yes, in rare cases, non-small cell lung cancer can transform into small cell lung cancer as a way to hide from targeted treatments. This happens when the cancer cells rewrite their identity to survive, usually requiring a change in your treatment plan to small cell-specific chemotherapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report show loss of TP53 and RB1?
  2. 2.Based on my biopsy, do I have a specific molecular subtype like SCLC-A or SCLC-I?
  3. 3.If I have a neuroendocrine subtype, does that change the type of chemotherapy or immunotherapy you recommend?
  4. 4.(If applicable) Since I was previously treated for NSCLC, did my cancer transform into SCLC, and how does that change my prognosis?
  5. 5.Are there clinical trials available specifically for my molecular subtype?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection.

    Wang Q, Gümüş ZH, Colarossi C, et al.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023; (18(1)):31-46 doi:10.1016/j.jtho.2022.10.002.

    PMID: 36243387
  2. 2

    ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.

    Xu G, Zhou L

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2024; (49(4)):628-636 doi:10.11817/j.issn.1672-7347.2024.230506.

    PMID: 39019792
  3. 3

    Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

    Offin M, Chan JM, Tenet M, et al.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019; (14(10)):1784-1793 doi:10.1016/j.jtho.2019.06.002.

    PMID: 31228622
  4. 4

    Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?

    Kawai H, Matsuoka R, Ito T, Matsubara D

    Frontiers in bioscience (Landmark edition) 2022; (27(3)):108 doi:10.31083/j.fbl2703108.

    PMID: 35345340
  5. 5

    p53 and RB1 regulate Hedgehog responsiveness via autophagy-mediated ciliogenesis.

    Cain JE, Watkins DN

    Molecular & cellular oncology 2020; (7(6)):1805095 doi:10.1080/23723556.2020.1805095.

    PMID: 33235907
  6. 6

    Recent Research on Role of p53 Family in Small-Cell Lung Cancer.

    Jeong M, Kim KB

    Cancers 2025; (17(7)) doi:10.3390/cancers17071110.

    PMID: 40227619
  7. 7

    NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment.

    Koba H, Kimura H, Yoneda T, et al.

    Translational lung cancer research 2021; (10(11)):4161-4173 doi:10.21037/tlcr-21-536.

    PMID: 35004247
  8. 8

    Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches.

    Liu S, Xu T, Cao X, et al.

    Biochimica et biophysica acta. Reviews on cancer 2025; (1880(5)):189413 doi:10.1016/j.bbcan.2025.189413.

    PMID: 40784437
  9. 9

    Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

    Rudin CM, Poirier JT, Byers LA, et al.

    Nature reviews. Cancer 2019; (19(5)):289-297 doi:10.1038/s41568-019-0133-9.

    PMID: 30926931
  10. 10

    Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities.

    Catania C, Cascetta P, Russo A, et al.

    Current oncology (Toronto, Ont.) 2025; (32(10)) doi:10.3390/curroncol32100536.

    PMID: 41149456
  11. 11

    Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.

    Megyesfalvi Z, Barany N, Lantos A, et al.

    The Journal of pathology 2022; (257(5)):674-686 doi:10.1002/path.5922.

    PMID: 35489038
  12. 12

    New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?

    Zhang B, Birer SR, Dvorkin M, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2021; (41()):1-10 doi:10.1200/EDBK_320673.

    PMID: 33979194
  13. 13

    Extensive-stage small-cell lung cancer: Current management and future directions.

    Yu Y, Chen K, Fan Y

    International journal of cancer 2023; (152(11)):2243-2256 doi:10.1002/ijc.34346.

    PMID: 36346100
  14. 14

    Molecular Pathology of Lung Cancer.

    J Saller J, Boyle TA

    Cold Spring Harbor perspectives in medicine 2022; (12(3)) doi:10.1101/cshperspect.a037812.

    PMID: 34751163
  15. 15

    Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

    Arbour KC, Riely GJ

    JAMA 2019; (322(8)):764-774 doi:10.1001/jama.2019.11058.

    PMID: 31454018
  16. 16

    A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy.

    Kobayashi N, Sunaga N, Yatomi M, et al.

    Thoracic cancer 2025; (16(2)):e15512 doi:10.1111/1759-7714.15512.

    PMID: 39731296
  17. 17

    Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

    Leonetti A, Sharma S, Minari R, et al.

    British journal of cancer 2019; (121(9)):725-737 doi:10.1038/s41416-019-0573-8.

    PMID: 31564718
  18. 18

    Primary de novo Epidermal Growth Factor Receptor Mutant Small Cell Lung Carcinomas: Clinicopathological Study of a Rare Entity Presenting in Treatment-Naïve Setting with Review of Literature.

    Nambirajan A, Rathor A, Baskarane H, et al.

    International journal of surgical pathology 2025; (33(7)):1593-1604 doi:10.1177/10668969251331591.

    PMID: 40289562
  19. 19

    Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

    Schoenfeld AJ, Chan JM, Kubota D, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2020; (26(11)):2654-2663 doi:10.1158/1078-0432.CCR-19-3563.

    PMID: 31911548
  20. 20

    Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma.

    Hakozaki T, Kitazono M, Takamori M, Kiriu T

    Internal medicine (Tokyo, Japan) 2020; (59(10)):1291-1294 doi:10.2169/internalmedicine.3542-19.

    PMID: 32101830
  21. 21

    Prevalence of Histological Transformation in First-Line Osimertinib Non-Small Cell Lung Cancers: Case Series and Literature Review.

    Sparavelli R, Bruno R, Celi A, et al.

    International journal of molecular sciences 2025; (26(21)) doi:10.3390/ijms262110462.

    PMID: 41226501

This page explains the biology and genetics of small cell lung cancer for educational purposes only. Always consult your oncologist to understand your specific pathology results and treatment options.

Get notified when new evidence is published on Small cell lung cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.